Cumulative clinical experience from over a decade of use of levofoxacin in community-acquired pneumonia: Critical appraisal and role in therapy

Drug, Healthcare and Patient Safety

Volumn 3, Issue 1, 2011, Pages 59-68

  Noreddin, Ayman M ^a   Elkhatib, Walid F ^b   Cunnion, Kenji M ^c   Zhanel, George G ^d  

^a HAMPTON UNIVERSITY   (United States)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Clinical use; Community acquired pneumonia; Levofoxacin; Pharmacodynamics; Pharmacokinetics; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIDIABETIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; INSULIN; LEVOFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; THEOPHYLLINE; WARFARIN;

ABDOMINAL PAIN; ACUTE BACTERIAL SINUSITIS; ACUTE PYELONEPHRITIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SINUSITIS; BIOEQUIVALENCE; CHRONIC BRONCHITIS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MEGADOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUTION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GENE; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GYRA GENE; GYRB GENE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; KIDNEY DYSFUNCTION; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LIVER DYSFUNCTION; LUNG ALVEOLUS MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIPLE DRUG DOSE; MYCOPLASMA PNEUMONIAE; NAUSEA; NEUTROPHIL; NOSOCOMIAL PNEUMONIA; PARANASAL SINUS; PARANASAL SINUS MUCOSA; PARC GENE; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PHOTOSENSITIVITY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RESPIRATORY TRACT INFECTION; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING;

EID: 84855263441     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15(4):757-763.
2. Gutierrez F, Masia M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect. 2005;11(10):788-800.
3. Loh LC, Khoo SK, Quah S Y, et al. Adult community-acquired pneumonia in Malaysia: prediction of mortality from severity assessment on admission. Respirology. 2004;9(3):379-386.
4. O'Meara ES, White M, Siscovick DS, Lyles M F, Kuller LH. Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. J Am Geriatr Soc. 2005;53(7):1108-1116.
5. Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53(3):166-174.
6. Kaplan V, Angus DC. Community-acquired pneumonia in the elderly. Crit Care Clin. 2003;19(4):729-748.
7. Viegi G, Pistelli R, Cazzola M, et al. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med. 2006;100(1):46-55.
8. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125(6):2140-2145.
9. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-1754.
10. Kollef MH, Shorr A, Tabak Y P, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128(6):3854-3862.
11. Bodi M, Rodriguez A, Sole-Violan J, et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005;41(12):1709-1716.
12. Tejerina E, Frutos-Vivar F, Restrepo MI, et al. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care. 2005;20(3):230-238.
13. Wilson PA, Ferguson J. Severe community-acquired pneumonia: an Australian perspective. Intern Med J. 2005;35(12):699-705.
14. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006;10 Suppl 2:S1.
15. File TM. Clinical implications and treatment of multi resistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect. 2006; 12 Suppl 3:31-41.
16. Lauderdale TL, Chang F Y, Ben RJ, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir. Med. 2005;99(9):1079-1086.
17. Leesik H, Ani U, Juhani A, Altraja A. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. Medicina (Kaunas). 2006;42(5):384-394.
18. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest. 2000;118(5):1344-1354.
19. Huang HH, Zhang YY, Xiu Q Y, et al. Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. Eur J Clin Microbiol Infect Dis. 2006;25(6):369-374.
20. Saito A, Kohno S, Matsushima T, et al. Prospective multi center study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother. 2006;12(2):63-69.
21. Thibodeau K P, Viera AJ. Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician. 2004;69(7):1699-1706.
22. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002;36: 20s-27s.
23. File TM Jr, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest. 2004;125(5): 1888-1901.
24. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-S72.
25. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6): 1138-1180.
26. Doern G V, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005;41(2):139-148.
27. Bonofglio L, Ojeda MI, de Mier C, et al. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital. Int J Antimicrob Agents. 2005;25(3):260-263.
28. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy. 2004;50 Suppl 1:3-10.
29. Fuller JD, McGeer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis. 2005;24(12):780-788.
30. Reinert RR, Reinert S, van der Linden M, Cil M Y, Al-Lahham A, Appelbaum P. Antimicrobial susceptibility of Streptococcus pneumo-niae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother. 2005;49(7):2903-2913.
31. Jones RN, Fritsche TR, Sader HS, Stilwell MG. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fuoroquinolone MIC values. Diagn Microbiol Infect Dis. 2007;58(1):9-17.
32. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus infuenzae collected from patients across the USA, in 2001-2002, as part of the PRO-TEKT US study. J Antimicrob Chemother. 2004;54 Suppl 1:i7-i15.
33. Doern G V, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J Infect. 2004;48(1):56-65.
34. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: fndings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis. 2003;45(4):251-259.
35. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003;36(8):963-970.
36. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:635-692.
37. Wang JC. A journey in the world of DNA rings and beyond. Annu Rev Biochem. 2009;78:31-54.
38. Huband MD, Cohen MA, Zurack M, et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother. 2007;51(4):1191-1201.
39. Croom KF, Goa KL. Levofoxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24): 2769-2802.
40. Keating GM, Scott LJ. Moxifoxacin: a review of its use in the management of bacterial infections. Drugs. 2004;64(20):2347-2377.
41. ® (levofoxacin tablets, oral solution, injection): US prescribing information. Raritan (NJ): Ortho-McNeil Pharmaceutical, Inc; Aug 2009.
42. Hurst M, Lamb HM, Scott LJ, Figgitt D P. Levofoxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127-2167.
43. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard - seventh edition. Clinical and Laboratory Standards Institute Document M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, Jan 2006:26(2).
44. Gordon KA, Sader HS, Jones RN. Contemporary re-evaluation of the activity and spectrum of grepafoxacin tested against isolates in the United States. Diagn Microbiol Infect Dis. 2003;47(1):377-383.
45. Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxa-cin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Microbiol Infect Dis. 2007; 58(1):19-26.
46. Goff DA, Dowzicky MJ. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol. 2007;56(Pt 9):1189-1193.
47. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fuoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the frst report of fuoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis. 2006;55(2):119-127.
48. Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fuoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260-3269.
49. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52(2):229-246.
50. Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus infuenzae, Haemophilus parainfuenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents.2004;23(3):296-299.
51. Hansen GT, Blondeau JM. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofoxacin, levofoxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 2005;17(5): 484-492.
52. Deshpande LM, Diekema DJ, Jones RN. Comparative activity of clinafoxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagn Microbiol Infect Dis. 1999;35(1):81-88.
53. Rolston K V, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH. Antimicrobial activity of a novel des-fuoro (6) quinolone, garenoxa-cin (BMS-284756): compared to other quinolones, against clinical isolates from cancer patients. Diagn Microbiol Infect Dis. 2002;44(2): 187-194
54. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus infuenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 2002;34 Suppl 1:S4-S16.
55. Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofoxacin in Streptococcus pneumoniae, Haemophilus infuenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother. 2003;47(6):1790-1797.
56. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27(6):468-475.
57. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofoxa-cin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect. 2002;8(4):214-221.
58. Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648): ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother. 2003;47(3): 1135-1136.
59. Kohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. Pneumoniae. Antimicrob Agents Chemother. 2004;48(5):1885-1886.
60. Hammerschlag MR, Roblin PM. The in vitro activity of a new fuo-roquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother. 2004;54(1):281-282.
61. Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiotic effect of gemifoxacin against Legionella spp. J Antimicrob Chemother. 2000;45 Suppl 1:41-46.
62. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents. 2005;25(4):302-307.
63. Waites KB, Crabb DM, Bing X, Duffy LB. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2003;47(1):161-165.
64. Waites KB, Crabb DM, Duffy LB. Comparative in vitro activities of the investigational fuoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2008;52(10):3776-3778.
65. Duffy LB, Crabb DM, Bing X, Waites KB. Bactericidal activity of levo-foxacin against Mycoplasma pneumoniae. J Antimicrob Chemother. 2003;52(3):527-528.
66. Dunbar LM, Wunderink RG, Habib M P, et al. High-dose, short-course levofoxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37(6):752-760.
67. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fuoroquinolone ABT-492 and other antimicrobial agents against human mycoplas-mas and ureaplasmas. Antimicrob Agents Chemother. 2003;47(12): 3973-3975.
68. Felmingham D, Feldman C, Hryniewicz W, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect. 2002;8 Suppl 2:12-42.
69. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fuoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother. 2003;52(6): 944-952.
70. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob. Agents. 2003;21(5):409-413.
71. Deryke CA, Du X, Nicolau D P. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profle of moxifoxacin and levofoxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006;58(3):601-609.
72. LaPlante KL, Rybak MJ, Tsuji B, Lodise T P, Kaatz G W. Fluoro-quinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifoxacin, gemifoxacin, levofoxacin, and moxifoxacin. Antimicrob Agents Chemother. 2007;51(4):1315-1320.
73. Sahm DF, Benninger MS, Evangelista AT, Yee YC, Thornsberry C, Brown N P. Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005). Otolaryngol Head Neck Surg. 2007;136(3):385-389.
74. West M, Boulanger BR, Fogarty C, et al. Levofoxacin compared with imipenem/cilastatin followed by ciprofoxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 2003;25(2):485-506.
75. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofoxacin in healthy volunteers. Antimicrob Agents Chemother. 2001;45(7):2122-2125.
76. Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofoxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42(4):885-888.
77. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofoxacin against fuoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents. 2008;32(4):320-325.
78. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofoxacin and ciprofoxacin in healthy adult subjects. Chest. 2001;119(4):1114-1122.
79. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofoxacin and azithromycin in healthy adults. Antimicrob Agents Chemother. 2003; 47(8):2450-2457.
80. Capitano B, Mattoes HM, Shore E, et al. Steady-state intrapulmonary concentrations of moxifoxacin, levofoxacin, and azithromycin in older adults. Chest. 2004;125(3):965-973.
81. Conte JE Jr, Golden JA, McIver M, Little E, Zurlinden E. Intrapul-monary pharmacodynamics of high-dose levofoxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents. 2007;30(5):422-427.
82. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofoxacin penetration into epithelial lining fuid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2002;46(2):586-589.
83. Pea F, Marioni G, Pavan F, et al. Penetration of levofoxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. Pharmacol Res. 2007;455(1):38-41.
84. Garraffo R, Lavrut T, Durant J, et al. In vivo comparative pharma-cokinetics and pharmacodynamics of moxifoxacin and levofoxacin in human neutrophils. Clin Drug Investig. 2005;25(10):643-650.
85. Poole M, Anon J, Paglia M, Xiang J, Khashab M, Kahn J. A trial of high-dose, short-course levofoxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg. 2006;134(1):10-17.
86. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofoxacin 750 mg once-daily for fve days with ciprofoxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71(1):17-22.
87. Klausner HA, Brown P, Peterson J, et al. A trial of levofoxacin 750 mg once daily for 5 days versus ciprofoxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23(11):2637-2645.
88. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Effcacy of 750-mg, 5-day levofoxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004;20(4):555-563.
89. Shorr A F, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofoxacin in a subgroup of patients aged $65 years with community-acquired pneumonia. Clin Ther. 2005; 27(8):1251-1259.
90. File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofoxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin. 2004;20(9):1473-1481.
91. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofoxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med. 2006;100(12):2129-2136.
92. Levofoxacin revisited. Med Lett Drugs Ther. 2011;53(1368):55.
93. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event pro-fles of levofoxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin. 2006;22(10):1997-2006.
94. Yee YC, Evangelista AT, Obot-Tucker M, et al. Five-year surveillance (2003-2007) of anti-pneumococcal activity of oral agents recommended for the empirical treatment of com munity-acquired pneumonia (CAP) in adults [Abstract No. C2 204]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, Sep 17-20, 2007.